Portfolio company
Holoclara
United States · £12.6m raised
Raised
£12.6m
Latest stage
Series A
Rounds recorded
1
Backed by
2 investors
Sectors
About
This company develops oral therapeutics derived from roundworm molecules to treat patients with allergic and autoimmune diseases.
SourceFunding history · 1
Similar companies
Ditto Biosciences
The company develops parasite-derived protein therapies for pharmaceutical and biotechnology partners to treat patients with autoimmune diseases using an artificial intelligence platform.
Merida Biosciences
This company develops precision immunology therapies to treat patients suffering from autoimmune and allergic disorders.
Iolyx Therapeutics
The company develops immunomodulatory medicines to treat ocular inflammation and autoimmune eye diseases for patients worldwide.
Dualyx
This company develops immune-modulating therapies targeting regulatory T cells to treat patients with autoimmune diseases.
Healome Therapeutics
The company develops eye-drop matrix technology to improve drug delivery and treatment for patients with ocular surface diseases.
Hillstar Bio
This biotechnology company develops precision immunology therapies that target and deplete pathogenic immune cells for patients with autoimmune diseases.
COUR Pharma
This clinical-stage biotechnology company develops nanoparticle therapies designed to restore immune tolerance for patients with autoimmune and inflammatory diseases.
Alumis
This company develops oral therapies and precision medicines for patients with immune-mediated disorders including plaque psoriasis and systemic lupus erythematosus.
